Deepak NitriteNSE:DEEPAKNTR
Current view Q1 2027
Makes phenol, acetone and specialty chemicals. It performed best while the foreign competitor's import duty was nil for the whole quarter; the duty was reapplied at quarter-end, so Q2 should be more profitable. Phenol output lifted by half for under ₹200 cr, promoter buying near ₹1,588. But 86% of segment profit is one spread, and polycarbonate slipped to FY29 at ₹11,500 cr from ₹5,000 cr.
Latest exchange filings last 5 · 5 after Q1 2027
- 26 Aug ’26DNL and DPL invested ₹175 crore in DCTL via OCRPS allotment on 26 August 2026. ↗
- 25 Aug ’26Subsidiary settled factories-rule violation for ₹3,00,000 on 25 August 2026. ↗
- 21 Aug ’26Puneet Sharma resigned as SBU Head - Life Sciences, effective close of business 21 August 2026. ↗
- 11 Aug ’26Announcement under Regulation 30 (LODR)-Earnings Call Transcript 11 Aug ↗
- 7 Aug ’26Board changes effective from August 7, 2026; updated 13-member board disclosed. ↗
Exchange filings, with the company's own one-line summary, read off the same page as the figures. Screener publishes only the most recent few, so this is the last 5 — not everything filed since your note, and a quiet-looking list is not proof of a quiet quarter. A filing is marked new when it is dated after the end of the quarter your note covers. Not scored, and not a judgement — a routine repayment notice and a takeover sit in the same list.
AI concall report · Q1 2027
The full earnings-call read behind this view — what management promised, what they delivered, and the earning trigger.
Growth Q1 2027
| Metric | This year vs lastYoY · vs Q1 2026 | vs the quarter beforeQoQ, sequential · vs Q4 2026 | 3-year yearly average3Y CAGR · compounded | 5-year yearly average5Y CAGR · compounded |
|---|---|---|---|---|
| Sales | ▲ +36.4% | +21.6% | −0.4% | +12.6% |
| Operating profit | ▲ +184.2% | +43.6% | −8.3% | −4.1% |
| EPS | ▲ +207.4% | +57.0% | −13.6% | −6.6% |
| PAT | ▲ +208.0% | +56.8% | — | — |
Tinted rows drive the Tier. Tier = the weaker of YoY Sales and YoY PAT growth. Here the weaker is Sales at +36.4%, which is ≥ 20% → Tier 1.
QoQ is sequential, not a trend. For most Indian companies the March quarter is seasonally the largest, so a June-quarter fall against it is a calendar effect. Only the YoY column feeds the Tier.
Multibagger potential
Poor21/100
⚠ Your own view here is Positive, and the figures are not. The note above is where the reason lives; the score only sees the numbers.
Earnings are shrinking, not growing. Profit per share fell 14% a year over the window measured. Nothing compounds from here until that turns, whatever the price does.
No forward view — earnings are not compounding, so there is nothing to project.
Multiple moved without the earnings — the return sits in sentiment.
How this is calculated
Band capped: earnings are not growing over the measured window.
Growth rate used: -13.6% — the weakest of EPS / Sales / Op-profit from 3-year EPS CAGR. Latest quarter reads 60%.
How it compares with its rivals Bulk Chemicals · 6 of 94 listed
It earns 11% on its capital, fifth of 6, and it is the fifth most expensive of the 6 shown.
| Company | Price | P/E | Size | ROCE | Profitlast qtr | Saleslast qtr |
|---|---|---|---|---|---|---|
| Deepak Nitrite | ₹1,605 | 27.6× | ₹21,892 Cr | 11.4% | +207.5% | +36.4% |
| Pidilite Inds. | ₹1,595 | 61.3× | ₹1.62 L Cr | 31.0% | +28.2% | +21.3% |
| Gujarat Fluoroch | ₹4,577 | 81.4× | ₹50,278 Cr | 9.6% | +21.4% | +24.0% |
| Navin Fluo.Intl. | ₹8,429 | 54.5× | ₹43,252 Cr | 21.0% | +107.7% | +44.1% |
| Aether Industri. | ₹1,639 | 90.7× | ₹21,754 Cr | 11.9% | +28.0% | +27.3% |
| Atul | ₹6,142 | 22.7× | ₹18,082 Cr | 14.9% | +92.0% | +25.0% |
Screener's own peer group, from the request already made for the industry P/E. It serves the industry's largest names by market cap, not companies of a similar size, so treat this as context rather than a like-for-like table; this company is always shown. On a phone the price, size and sales columns are dropped rather than pushed off the edge. Not part of the score.
Business quality to Jun 2026
| Are the margins widening? | wider, but it has moved around a lot | operating margin 12% → 21% over 3 years |
|---|---|---|
| Did the profit turn into cash? | most of it arrived as cash | 74% last year, 84% over three · free cash flow −₹658 cr, positive in 3 of 5 years |
| Is the growth borrowed? | lightly borrowed | ₹1,638 cr — 0.28× its own equity (was 0.24×) |
| Is it being collected? | collection is steady | 70 days to collect, up 14 in a year · cash cycle 92 days |
| Who has been buying? | the promoters have held steady | promoters 49.3% (+0.1 in a year), 49.1% → 49.3% over 2.8 years · FIIs 6.2% (−0.4) · DIIs 23.8% (+1.1) · shareholders 5,72,562 → 3,82,905 |
| What does it earn on its capital? | earns little on its capital | ROCE 11.4% · ROE 9.8% |
Fetched from the filings, not typed — and deliberately not part of the score. These are the questions the score cannot ask: it reads growth, price and trend, so a company can score well while its profit never becomes cash. Weigh these beside the note, not against the number.
Screener's own checklist not mine, not the score
Against it
- Company has a low return on equity of 12.8% over last 3 years.
- Company might be capitalizing the interest cost
Generated by screener.in from a fixed checklist — not written by me and not an input to the score. It is here as a second machine opinion to weigh against the note; where it disagrees with the view above, the note is the considered one.